Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline

Journal of Clinical Oncology

Volumn 34, Issue 25, 2016, Pages 3069-3103

  Rugo, Hope S ^a   Rumble, R Bryan ^a   Macrae, Erin ^a   Barton, Debra L ^a   Connolly, Hannah Klein ^a   Dickler, Maura N ^a   Fallowfield, Lesley ^a   Fowble, Barbara ^a   Ingle, James N ^a   Jahanzeb, Mohammad ^a   Johnston, Stephen R D ^a   Korde, Larissa A ^a   Khatcheressian, James L ^a   Mehta, Rita S ^a   Muss, Hyman B ^a   Burstein, Harold J ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; HORMONE RECEPTOR; PALBOCICLIB; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BIOLOGICAL THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; DISEASE FREE INTERVAL; HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER; HUMAN; LOADING DRUG DOSE; METASTATIC BREAST CANCER; PREMENOPAUSE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR GROWTH; BREAST NEOPLASMS; FEMALE; METABOLISM; PRACTICE GUIDELINE;

BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84983472002     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.1487     Document Type: Article

References (98)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
2. Clarke CA, Keegan TH, Yang J, et al: Agespecific incidence of breast cancer subtypes: Understanding the black-white crossover. J Natl Cancer Inst 104:1094-1101, 2012
3. Lobbezoo DJ, van Kampen RJ, Voogd AC, et al: Prognosis of metastatic breast cancer subtypes: The hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 141:507-514, 2013
4. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N Engl J Med 366:520-529, 2012
5. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
6. Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529-5537, 2009
7. Finn RS, Crown JP, Lang I, et al: The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/ TRIO-18): A randomised phase 2 study. Lancet Oncol 16:25-35, 2015
8. Wilcken N, Hornbuckle J, Ghersi D: Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2:CD002747, 2003
9. Robertson JFR, Paridaens R, Bogaerts J, et al: Visceral metastases from hormone receptor positive breast cancer are as sensitive to endocrine therapy as non-visceral metastases. Cancer Res 75 , 2015 (abstr P1-13-02)
10. Sledge GW Jr, Hu P, Falkson G, et al: Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormonesensitive breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 18:262-266, 2000
11. Pritchard KI: Combining endocrine agents with chemotherapy: Which patients and what sequence? Cancer 112:718-722, 2008 (suppl)
12. Partridge A, Rumble RB, Carey LA, et al: Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:3307-3329, 2014
13. Mehta RS, Barlow WE, Albain KS, et al: Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367:435-444, 2012
14. Bergh J, Jönsson PE, Lidbrink EK, et al: FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30:1919-1925, 2012
15. Robertson JF, Lindemann JP, Llombart-Cussac A, et al: Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 136:503-511, 2012
16. Robertson JFR, Llombart-Cussac A, Feltl D, et al: Fulvestrant 500 mg versus anastrozole as firstline treatment for advanced breast cancer: Overall survival from the phase II 'FIRST' study. Cancer Res 75, 2015 (abstr S6-04)
17. Yardley DA, Noguchi S, Pritchard KI, et al: Everolimus plus exemestane in postmenopausal patients with HR(1) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30: 870-884, 2013 (erratum: Adv Ther 31:1008-1009, 2014)
18. Turner NC, Ro J, André F, et al: Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373:209-219, 2015
19. Klijn JG, Beex LV, Mauriac L, et al: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 92:903-911, 2000
20. Klijn JG, Blamey RW, Boccardo F, et al: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001
21. Chia S, Gradishar W, Mauriac L, et al: Doubleblind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT. J Clin Oncol 26:1664-1670, 2008
22. Di Leo A, Jerusalem G, Petruzelka L, et al: Final analysis of overall survival for the phase III CONFIRM trial: Fulvestrant 500 mg versus 250 mg. Cancer Res 72, 2012 (abstr S1-4)
23. Iwata H, Masuda N, Ohno S, et al: A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormonereceptor-positive advanced breast cancer. Breast Cancer Res Treat 139:441-451, 2013
24. Llombart-Cussac A, Ruiz A, Antón A, et al: Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial. Cancer 118:241-247, 2012
25. Ohno S, Rai Y, Iwata H, et al: Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: Results from a double-blind, phase II comparative study (FINDER1). Ann Oncol 21:2342-2347, 2010
26. Pritchard KI, Rolski J, Papai Z, et al: Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat 123:453-461, 2010
27. Xu B, Jiang Z, Shao Z, et al: Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: Results of a multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol 67:223-230, 2011
28. Amir E, Clemons M, Purdie CA, et al: Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multidisciplinary prospective studies. Cancer Treat Rev 38:708-714, 2012
29. Amir E, Miller N, Geddie W, et al: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30:587-592, 2012
30. Pusztai L, Viale G, Kelly CM, et al: Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 15:1164-1168, 2010
31. Chi F, Wu R, Zeng Y, et al: Effects of toremifene versus tamoxifen on breast cancer patients: A meta-analysis. Breast Cancer 20:111-122, 2013
32. Cope S, Ouwens MJ, Jansen JP, et al: Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: A network meta-analysis with parametric survival models. Value Health 16:403-417, 2013
33. Xu HB, Liu YJ, Li L: Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: A literature-based meta-analysis. Clin Breast Cancer 11:246-251, 2011
34. Tan PS, Haaland B, Montero AJ, et al: Anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer: A meta-analysis. J Clin Oncol 31, 2013 (suppl; abstr e11591)
35. Valachis A, Mauri D, Polyzos NP, et al: Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol 73: 220-227, 2010
36. Bachelot TD, Jerusalem GHM, Cikalo M, et al: Comparative efficacy of everolimus versus fulvestrant for hormone-receptor-positive (HR1) advanced breast cancer (ABC) following progression/recurrence after first-line treatment: A network meta-analysis. J Clin Oncol 31, 2013 (suppl; abstr e11602)
37. Di Leo A, Jerusalem G, Petruzelka L, et al: Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 106:djt337, 2014
38. Paridaens RJ, Dirix LY, Beex LV, et al: Phase III study comparing exemestane with tamoxifen as firstline hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 26:4883-4890, 2008
39. Johnston SR, Kilburn LS, Ellis P, et al: Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormonereceptor-positive locally advanced or metastatic breast cancer (SoFEA): A composite, multicentre, phase 3 randomised trial. Lancet Oncol 14:989-998, 2013
40. Johnston SRD, Basik M, Hegg R, et al: Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). J Clin Oncol 31, 2013 (suppl; abstr 531)
41. Burstein HJ, Cirrincione CT, Barry WT, et al: Endocrine therapy with or without inhibition of epidermal growth factor and human epidermal growth factor receptor 2: A randomized, double-blind, placebocontrolled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol 32:3959-3966, 2014
42. Huober J, Fasching PA, Barsoum M, et al: Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer: Results of the eLEcTRA trial. Breast 21:27-33, 2012
43. Schwartzberg LS, Franco SX, Florance A, et al: Lapatinib plus letrozole as first-line therapy for HER-21 hormone receptor-positive metastatic breast cancer. Oncologist 15:122-129, 2010 (Erratum: Oncologist 15:327, 2010)
44. Bachelot T, Bourgier C, Cropet C, et al: Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 30:2718-2724, 2012
45. Wolff AC, Lazar AA, Bondarenko I, et al: Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31:195-202, 2013
46. Piccart M, Hortobagyi GN, Campone M, et al: Everolimus plus exemestane for hormone-receptorpositive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from BOLERO-2. Ann Oncol 25:2357-2362, 2014
47. Clemons MJ, Cochrane B, Califaretti N, et al: Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study-NCT00811369. J Clin Oncol 31, 2013 (suppl; abstr 574)
48. Robertson JF, Ferrero J-M, Bourgeois H, et al: Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormonereceptor-positive breast cancer: A randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 14: 228-235, 2013
49. Martín M, Loibl S, von Minckwitz G, et al: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: The letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 33:1045-1052, 2015
50. Dickler MN, Barry WT, Cirrincione CT, et al: Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). J Clin Oncol 33, 2015 (suppl; abstr 501)
51. Yardley DA, Ismail-Khan RR, Melichar B, et al: Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31:2128-2135, 2013
52. Krop I, Johnston S, Mayer IA, et al: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER1, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer: Part I results. Cancer Res 75, 2015 (abstr S2-02)
53. Baselga J, Im SA, Iwata H, et al: PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR1/HER2- advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2015
54. Di Leo A, Jerusalem G, Petruzelka L, et al: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptorpositive advanced breast cancer. J Clin Oncol 28: 4594-4600, 2010
55. Rugo HS, Pritchard KI, Gnant M, et al: Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2. Ann Oncol 25: 808-815, 2014
56. Rugo HS: Dosing and safety implications for oncologists when administering everolimus to patients with hormone receptor-positive breast cancer. Clin Breast Cancer 16:18-22, 2016
57. Yardley DA, Hortobagyi GN, Lebrun F, et al: Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2. J Clin Oncol 31, 2013 (suppl; abstr 553)
58. Bonneterre J, Thürlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex RandomizedGroup Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000
59. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
60. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol 18:3758-3767, 2000
61. Suman VJ, Ellis MJ, Ma CX: The ALTERNATE trial: Assessing a biomarker driven strategy for the treatment of post-menopausal women with ER1/Her2-invasive breast cancer. Chin Clin Oncol 4:34, 2015
62. Taylor CW, Green S, Dalton WS, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. J Clin Oncol 16:994-999, 1998
63. Ingle JN, Krook JE, Green SJ, et al: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178-185, 1986
64. Crump M, Sawka CA, DeBoer G, et al: An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 44:201-210, 1997
65. Carlson RW, Theriault R, Schurman CM, et al: Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 28:3917-3921, 2010
66. Cheung KL, Agrawal A, Folkerd E, et al: Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer 46: 2936-2942, 2010
67. Nishimura R, Anan K, Yamamoto Y, et al: Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial. Oncol Rep 29:1707-1713, 2013
68. Gnant M, Pfeiler G, Stöger H, et al: The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: An analysis of the randomised ABCSG-6a trial. Br J Cancer 109:589-596, 2013
69. Goodwin PJ: Obesity, insulin resistance and breast cancer outcomes. Breast 24:S56-S59, 2015 (suppl 2)
70. Gibson L, Lawrence D, Dawson C, et al: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 4:CD003370, 2009
71. Abrams J, Aisner J, Cirrincione C, et al: Doseresponse trial of megestrol acetate in advanced breast cancer: Cancer and Leukemia Group B phase III study 8741. J Clin Oncol 17:64-73, 1999
72. Ellis MJ, Gao F, Dehdashti F, et al: Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study. JAMA 302:774-780, 2009
73. Howell A, Dodwell DJ, Anderson H, et al: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3: 611-617, 1992
74. Van Poznak C, Somerfield MR, Bast RC, et al: Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 33:2695-2704, 2015
75. Aapro M, Andre F, Blackwell K, et al: Adverse event management in patients with advanced cancer receiving oral everolimus: Focus on breast cancer. Ann Oncol 25:763-773, 2014
76. Pfizer: www.pfizer.com/news/press-release/ press-release-detail/pfizer-announces-positive-top- line-results-for-phase-3-paloma-2-clinical-trial-of- ibrance-palbociclib
77. Vidula N, Rugo HS: Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: A review of preclinical and clinical data. Clin Breast Cancer 16:8-17, 2016
78. Reisenbichler ES, Lester SC, Richardson AL, et al: Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: A demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification. Am J Clin Pathol 140:487-494, 2013
79. Thompson AM, Jordan LB, Quinlan P, et al: Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: The Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 12:R92, 2010
80. Yamashita H, Yando Y, Nishio M, et al: Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13:74-83, 2006
81. Wolff AC, Hammond MEH, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
82. Cheang MC, Martin M, Nielsen TO, et al: Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist 20:474-482, 2015
83. Tobin NP, Harrell JC, Lövrot J, et al: Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol 26:81-88, 2015
84. Giordano SH, Temin S, Kirshner JJ, et al: Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078-2099, 2014
85. Prat A, Baselga J: The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5:531-542, 2008
86. Jeselsohn R, Buchwalter G, De Angelis C, et al: ESR1 mutations: A mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol 12:573-583, 2015
87. André F, Cortés J: Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat 150:1-8, 2015
88. Johnston SR: Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: Cotargeting signaling pathways. J Natl Cancer Inst 107:djv212, 2015
89. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266, 2009
90. Fagerlin A, Zikmund-Fisher BJ, Ubel PA: Helping patients decide: Ten steps to better risk communication. J Natl Cancer Inst 103:1436-1443, 2011
91. Butow PN, Dowsett S, Hagerty R, et al: Communicating prognosis to patients with metastatic disease: What do they really want to know? Support Care Cancer 10:161-168, 2002
92. Hagerty RG, Butow PN, Ellis PA, et al: Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22:1721-1730, 2004
93. Lux MP, Bayer CM, Loehberg CR, et al: Shared decision-making in metastatic breast cancer: Discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. Breast Cancer Res Treat 139:429-440, 2013
94. American Cancer Society: Cancer Facts & Figures for African Americans 2011-2012. www.cancer.org/ acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-027765.pdf
95. American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity: Patient-centered care for older adults with multiple chronic conditions: A stepwise approach from the American Geriatrics Society-American Geriatrics Society Expert Panel on the care of older adults with multimorbidity. J Am Geriatr Soc 60:1957-1968, 2012
96. Howlader N, Krapcho M, Neyman N, et al (eds): SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). http://seer.cancer.gov/ archive/csr/1975-2009-pops09/
97. US Cancer Statistics Working Group: United States Cancer Statistics: 1999-2008 Incidence and Mortality Web-Based Report. https://nccd.cdc. gov/uscs/
98. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. www.commonwealthfund.org/usr-doc/ Mead-racialethnicdisparities-chartbook-1111.pdf